Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959508 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL2171004 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27144 | 0.83 | ALDH1A1 (0.68) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL23333463 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Guanidine SCHEMBL27358697 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL9133695 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL13267044 | 0.81 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27327716 | 0.81 | ALDH1A1 (0.66) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL23542519 | 0.81 | ALDH1A1 (0.66) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27831589 | 0.81 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| CN-106279369-B | Antifungal agent and application thereof | 奇达拉治疗公司 | 2020-02-11 | — | — | CN | disclosed |
| EP-2680873-A2 | ANTIFUNGAL AGENTS AND USES THEREOF | Seachaid Pharmaceuticals, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013040789-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| CN-102725401-A | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | HARVARD COLLEGE | 2012-10-10 | — | — | CN | disclosed |
| WO-2012119065-A2 | ANTIFUNGAL AGENTS AND USES THEREOF | SEACHAID PHARMACEUTICALS, INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2451944-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2012-05-16 | — | — | EP | disclosed |
| CN-102112121-A | Methods, compositions, and kits for treating pain and pruritis | HARVARD COLLEGE | 2011-06-29 | — | — | CN | disclosed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2101819-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008063603-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-05-29 | — | — | WO | disclosed |
| CN-101160280-A | Compounds and uses thereof | COMBINATORX INC (US) | 2008-04-09 | — | — | CN | disclosed |
| US-6284914-B1 | HYDROXAMIC ACID DERIVATIVES | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2001-09-04 | — | — | US | disclosed |
| US-6147114-A | HYDROXAMIC ACID DERIVATIVES FROM TUMOR NECROSIS FACTOR CONVERTING ENZYME | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-11-14 | — | — | US | disclosed |
| US-5563268-A | FOR PREVENTING CELL AGGLOMERATION, TREATING THROMBOSIS, ARTERIOSCLEROSIS, BRAIN, LUNG OR CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-10-08 | — | — | US | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| US-5418233-A | FOR INHIBITING CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1995-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | ALDH1A1 3650/4885TDP1 1208/4885MAPK1 4065/4885 |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | ALDH1A1 3650/4885TDP1 1208/4885MAPK1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.